Navigation Links
CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
Date:1/11/2010

ove patients' overall survival by 33% over what can be attained with standard treatment alone (without the addition of Multikine therapy) at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for this Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients having squamous cell carcinoma (cancer) of the head and neck.

About Multikine

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received surgery, chemotherapy and/or radiation therapy, which can limit their effectiveness.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also devel
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
4. CEL-SCI Expands H1N1 Flu Virus Work
5. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
6. CEL-SCI Posts New Corporate Presentation to Website
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SHANGHAI, March 5, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the pharmaceutical, ... and the United States, today announced its financial results ... Fourth-Quarter 2014 Highlights , Net Revenues ... , Laboratory Services Net Revenues Grew 17.7% Year Over ...
(Date:3/5/2015)... Germany , March 5, 2015 ... and CureVac today announced that the foundation has ... million) in CureVac, a leading clinical-stage biopharmaceutical company ... the agreement, the foundation will also provide separate ... based on CureVac,s proprietary messenger RNA (mRNA) platform. ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/6/2015)... California (PRWEB) March 06, 2015 ... one of the most common forms of cancer and ... Breast cancer can be screened through various techniques and ... Mammography however remains the gold standard technique in breast ... as cost, time taken for the procedure, required expertise ...
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 Ticket ... tickets . This popular ticket exchange has extended their customer ... hails from Hebden Bridge, West Yorkshire England and he began ... 2005. In the past couple of years Ed Sheeran ... though whenever Ed Sheeran is on stage he is having ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Further solidifying ... , Medical Doctor Associates announced today that the company ... after winning the Best of Staffing Talent Award five ... Inavero’s Best of Staffing Talent Diamond winners are proven ... given to them by the individuals they have helped ...
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Magellan Rx ... only comprehensive source for key trends and statistics on ... medical injectables. Executives from Magellan Rx Management will discuss ... Report: Discover Your Hidden Specialty Drug Spend,” a complimentary ... Services, Inc. , Specialty drug spend makes up more ...
Breaking Medicine News(10 mins):Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... available in German . , Scientists from the ... lived off more than 100 million years ago. They want to ... as they did. In actual fact such gigantic animals should not ... in the journal ,Proceedings of the Royal Society B,. , Take ...
... & Melinda Gates Foundation to ... in 11 new countries, OAK BROOK, Ill., Feb. 6 ... it has received a $24.2 million grant from the Bill ... Micro Insurance Agency, greatly expand its insurance,products to the poor ...
... allayed some panic about suspected cancer-causing agents, such as ... has been developed through the Cancer Control Program at ... University of New South Wales (UNSW) researcher, Professor Bernard ... level of risk is high say, on a ...
... Feb. 6 Parental Alienation Awareness,Organization (PAAO) is beginning ... for April 25th - Parental Alienation Awareness Day., ... until they,experience it, parental alienation awareness was put forth ... The mission of PAAO is to help the ...
... PALO ALTO, Calif., Feb. 6 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... fourth quarter and full year 2007 financial results on ... financial markets. Jazz,Pharmaceuticals will host an investor conference call ... updates on February 13, 2008, at,5:00 p.m. Eastern Time/2:00 ...
... The Female Health Company,(Amex: FHC ) today announced ... the Premarket Approval Application (PMA) it submitted for,its second ... The Center for Devices and Radiological Health (CDRH) received,FHC,s ... Health Company, Inc., The Female Health Company, based ...
Cached Medicine News:Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 2Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 4Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 5Health News:Reducing cancer panic 2Health News:Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th 2Health News:Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008 2Health News:The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Identity pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
Medicine Products: